Drugs News and Research

RSS

Bioengineers build novel tool to visualize protein networks from breast cancer cell data

A colorful wheel developed by Rice University bioengineers to visualize protein interactions has won an international competition for novel strategies to study the roots of breast cancer.

21 Oct 2013

New investigational drug offers potential treatment option for lung cancer

PF-06463922, an investigational drug being developed by Pfizer Inc., has the potential to become a new treatment option for patients who have lung cancer harboring abnormalities in the ALK gene, according to preclinical results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.

21 Oct 2013

Inovio Pharmaceuticals begins phase I clinical trial for hepatitis C vaccine

Inovio Pharmaceuticals, Inc. announced today that the safety, tolerability and immunogenicity of its therapeutic vaccine for hepatitis C (INO-8000/VGX-6150) will be studied in a phase I clinical trial in chronically HCV infected patients.

21 Oct 2013

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Cytos Biotechnology Ltd ("Cytos" or the "Company") today announced that patient enrolment has been completed in the on-going phase 2b study with its lead product CYT003.

21 Oct 2013

Breast milk purchased over Internet contained bacteria that can cause illness in infants

Results from a study led by researchers at Nationwide Children's Hospital found more than three-fourths of breast milk samples purchased over the Internet contained bacteria that can cause illness, and frequently exhibited signs of poor collection, storage or shipping practices.

21 Oct 2013

New small-molecule inhibitor shows promising results in drug-resistant melanoma, breast cancer

LEE011, a small-molecule inhibitor of cyclin-dependent kinases (CDK) 4/6 being developed by Novartis Oncology, showed promising results in drug-resistant melanoma and drug-resistant breast cancer when tested in combination with other targeted therapies, and based on these preclinical results, several phase I clinical trials were launched recently, according to results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held October 19-23.

21 Oct 2013

Clarified role of signal-relay proteins may help explain spread of cancer

Cell biologists at The Johns Hopkins University have teased apart two integral components of the machinery that causes cells to move. Their discovery shows that cellular projections, which act as hands to help a cell "crawl," are apparently always initiated by a network of message-relaying proteins inside the cell.

21 Oct 2013

Researchers identify key therapeutic target for cancers driven by KRAS protein

Patients with cancers driven by the protein KRAS, which are particularly hard to treat, may benefit from small molecules that attach to and disrupt the function of a KRAS-containing protein complex, according to results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.

20 Oct 2013

Pfizer announces top-line results from phase 3b studies with Lyrica Capsules

Pfizer Inc. (NYSE:PFE) announced top-line results from two phase 3b, placebo-controlled studies with Lyrica® (pregabalin) Capsules CV in patients with fibromyalgia (FM) and painful diabetic peripheral neuropathy (DPN), respectively.

19 Oct 2013

Phase 2b study of JAK3 inhibitor VX-509 shows improvement in people with active RA

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced 12-week results from an ongoing Phase 2b study of VX-509, an investigational oral, selective Janus kinase 3 (JAK3) inhibitor, dosed once or twice daily in people with active rheumatoid arthritis (RA) taking methotrexate

19 Oct 2013

New study guides clinicians and policy makers on cost-effectiveness of anticoagulant drugs

Patients who are responding below par to the anticoagulant drug warfarin have several options. They can undergo even more blood tests to monitor their response to the different dosages of this medication which is prescribed to prevent strokes, or they could start using one of the newer, yet more expensive, anticoagulants on the market.

19 Oct 2013

FDA approves Iroko Pharmaceuticals’ ZORVOLEX capsules

Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today announced that the U.S. Food and Drug Administration (FDA) has approved ZORVOLEX™ (diclofenac) capsules, a nonsteroidal anti-inflammatory drug (NSAID), for the treatment of mild to moderate acute pain in adults. ZORVOLEX was approved at dosage strengths that are 20 percent lower than currently available diclofenac products.

19 Oct 2013

Alimera Sciences receives Complete Response Letter for New Drug Application from FDA

Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it has received a Complete Response Letter (CRL) for the New Drug Application (NDA) for ILUVIEN® from the U.S. Food and Drug Administration (FDA).

19 Oct 2013

Thomson Reuters adds Cortellis Clinical Trials Intelligence for drug discovery and development

The Intellectual Property & Science business of Thomson Reuters, the world's leading provider of intelligent information for businesses and professionals, today announced the addition of Clinical Trials Intelligence to the Thomson Reuters CortellisTM suite, the industry's most comprehensive information solution for drug discovery and development.

19 Oct 2013

Research roundup: Less savings needed for retirement health expenses; falls as a predictor of surgical outcomes

Each week, KHN compiles a selection of recently released health policy studies and briefs.

19 Oct 2013

Wnt5A signaling pathway helps researchers determine who may respond to BRAF inhibitors

One of the challenges of understanding cancer is trying to determine the mechanisms that drive metastasis, or the process by which tumor cells are able to spread throughout the body.

19 Oct 2013

Study: Skin tanning gene linked to higher risk for testicular cancer in white men

A gene important in skin tanning has been linked to higher risk for testicular cancer in white men, according to a study led by scientists from the U.S. National Institutes of Health and the University of Oxford in England.

19 Oct 2013

Opsumit drug receives FDA approval to treat adults with pulmonary arterial hypertension

The U.S. Food and Drug Administration today approved Opsumit (macitentan), a new drug to treat adults with pulmonary arterial hypertension (PAH), a chronic, progressive and debilitating disease that can lead to death or the need for lung transplantation.

19 Oct 2013

ARIAD discontinues Phase 3 EPIC trial of Iclusig in patients with chronic myeloid leukemia

ARIAD Pharmaceuticals, Inc. today announced that it is discontinuing the Phase 3 EPIC (Evaluation of Ponatinib versus Imatinib in Chronic Myeloid Leukemia) trial of Iclusig (ponatinib) in patients with newly diagnosed chronic myeloid leukemia.

18 Oct 2013

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

UCB announced today that the U.S. Food and Drug Administration has approved Cimzia (certolizumab pegol) for the treatment of adults with active ankylosing spondylitis.

18 Oct 2013

Drugs News and Research

Bioengineers build novel tool to visualize protein networks from breast cancer cell data

New investigational drug offers potential treatment option for lung cancer

Inovio Pharmaceuticals begins phase I clinical trial for hepatitis C vaccine

Cytos Biotechnology enrolls patients in Phase 2b study of CYT003 for treatment of allergic asthma

Breast milk purchased over Internet contained bacteria that can cause illness in infants

New small-molecule inhibitor shows promising results in drug-resistant melanoma, breast cancer

Clarified role of signal-relay proteins may help explain spread of cancer

Researchers identify key therapeutic target for cancers driven by KRAS protein

Pfizer announces top-line results from phase 3b studies with Lyrica Capsules

Phase 2b study of JAK3 inhibitor VX-509 shows improvement in people with active RA

New study guides clinicians and policy makers on cost-effectiveness of anticoagulant drugs

FDA approves Iroko Pharmaceuticals’ ZORVOLEX capsules

Alimera Sciences receives Complete Response Letter for New Drug Application from FDA

Thomson Reuters adds Cortellis Clinical Trials Intelligence for drug discovery and development

Research roundup: Less savings needed for retirement health expenses; falls as a predictor of surgical outcomes

Wnt5A signaling pathway helps researchers determine who may respond to BRAF inhibitors

Study: Skin tanning gene linked to higher risk for testicular cancer in white men

Opsumit drug receives FDA approval to treat adults with pulmonary arterial hypertension

ARIAD discontinues Phase 3 EPIC trial of Iclusig in patients with chronic myeloid leukemia

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News